Beaufort Securities view on Motif Bio PLC today

Beaufort Securities view on Motif Bio PLC: The appointment of The Fulford Group, a specialist strategic adviser in the healthcare sector, is an important step towards the commercialisation of iclaprim. Motif intends to commercialise iclaprim directly in the US, the largest pharmaceutical market in the World, while out-licensing other territories to strategic partners in view of generating additional development capital. With trials expected to complete in the second half of 2017, Management is keen to begin engaging with strategic partners to commercialise its lead product candidate whilst retaining the all-important rights for iclaprim in the US, the largest pharmaceutical market in the World. The Fulford Group will be instrumental in the delivery of such partnerships. Beaufort retains its Speculative Buy recommendation on Motif Bio plc.

 

Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, yesterday announced the appointment of specialist adviser, The Fulford Group Ltd, to assist Motif in developing and implementing strategies to commercialise iclaprim. Iclaprim is the Company’s lead antibiotic, which is currently in pivotal Phase 3 trials for the treatment of acute bacterial skin and skin structure infections (ABSSSIs), in territories outside of the USA. The Company expects that such partnerships could provide the Company with additional development capital in the form of upfront payments, milestone payments and ongoing royalty fees.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Motif Bio Plc

    More articles like this

    Motif Bio Plc

    Motif Bio plc Proposed Placing to raise approximately £19.4m

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today its intention to raise approximately £19.4 million (US$25 million), before expenses, by way of a conditional placing with new and

    Motif Bio Plc

    Motif Bio PLC Reports Year-End 2016 Financial Results

    Motif Bio PLC (LON:MTFB), a clinical stage biopharmaceutical company specializing in developing novel antibiotics, today announced financial results for the year ended December 31, 2016. Motif Bio made significant progress in 2016 towards our goal of

    Motif Bio Plc

    Motif Bio plc Update post NASDAQ IPO

    Motif Bio plc (LON:MTFB, NASDAQ:MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company

    Motif Bio Plc

    Motif Bio plc appoint ex NASDAQ listed Tyme Technologies CFO

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that Robert Dickey IV has been appointed as Chief Financial Officer. Mr. Dickey is an accomplished financial professional

    Motif Bio Plc

    Motif Bio PLC Update on US Public Offering

    Motif Bio plc (LON:MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, further to its announcement of 9 August 2016, said today that it is continuing to work towards pricing of its proposed public

    Motif Bio Plc

    Motif Bio plc 2 posters at ID Week in New Orleans

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has told DirectorsTalk that it will be presenting two poster studies at IDWeek, October 26 to 30 in New Orleans, USA.

    Motif Bio Plc

    Motif Bio plc progressing trials efficiently with latest update

    Motif Bio plc (AIM: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has given DirectorsTalk an update to REVIVE-1, one of Motif Bio’s two Phase 3 clinical trials currently enrolling patients with Acute